Sign in
CompletedPhase 3

KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP

Key facts

Who runs it
Julia Bielicki
Where
Germany and Switzerland13 sites in 2 countriesChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
510 people enrolled
Started
28 Oct 2018
Ended
26 Mar 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Celestamine®
Record updated
24 February 2025

Who can take part

Age
6 months to 14 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Body weight between 5 kg and 45 kg
  • Admission to hospital (i.e. assignment of an inpatient case number)
  • Clinical diagnosis of CAP (according to predefined criteria)
  • Parent and/or child (as age-appropriate) willing to accept all possible randomised allocations and to be contacted by telephone weekly up to and including at 4 weeks after randomisation
  • Informed consent form for trial participation signed by parent

Who cannot take part

  • Inability to tolerate oral medication
  • Completion of a course of systemic corticosteroids within 2 weeks from enrolment for courses of >5 days
  • Participation in another study with investigational drug within the 30 days preceding and during the present study
  • Previous enrolment into the current study
  • Chronic underlying disease associated with an increased risk of very severe CAP or CAP of unusual aetiology
  • Bilateral wheezing without focal chest signs AND clinical indication for primary administration of steroids (most likely to represent respiratory tract infection affecting the medium airways, i.e. not pneumonia)
  • Documented allergy or any other known contraindication to any trial medication
  • Subacute or chronic conditions requiring higher betamethasone equivalent or known primary or secondary adrenal insufficiency
  • Known diabetes mellitus (type 1)
  • Presence of local chest complications
  • Admission to hospital with a primary clinical diagnosis of bronchiolitis
  • Hospitalisation within the last two weeks preceding current admission with the possibility that pneumonia could be hospital-acquired or healthcare-associated
  • Transfer for any reason to a non-participating hospital directly from the paediatric emergency department
  • Parent are unlikely to be able to reliably participate in telephone follow-up because of significant language barriers
  • Enrolment of the investigator, his/her family members, and other dependent persons

This trial has no sites in United States.

It has sites in 2 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to concurrently evaluate whether adjunct treatment with corticosteroids in children hospitalized with CAP is more effective in terms of the proportion of children reaching clinical stability and whether such adjunct treatment is no worse in terms of CAP relapse.

The 2 groups in the trial

  • Celestamine® N 0.5Existing treatment, for comparison

    oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg

    Treatment: Celestamine®

  • PlaceboPlacebo, for comparison

    oral placebo matched to the product described above

    Treatment: Celestamine®

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised Placebo-controlled Multi-centre Effectiveness Trial of Adjunct Betamethasone Therapy in Hospitalised Children With Community Acquired Pneumonia (CAP)
Publications
Record updated
24 February 2025